Advanced Healthcare Materials · 2021 · 24 citations · 40 references
PharmacyOncologyPharmaceuticsDrug DeliveryImmunotherapyNanoparticle Drug DeliveryCancer ImmunotherapyCancer NanomedicineNanomedicineNanoparticle Delivery SystemsPhotothermal TherapyTargeted TherapyCancer Immunotherapy NanoparticlesCancer NanotherapyCancer Photothermal TherapyLocalized Drug DeliveryNanomaterials For Photothermal TherapyPd-l1 BlockadePhotothermal EffectsTumor-targeted Drug Delivery
The major obstacles of anti-PD therapy in metastatic tumors are limited drug delivery in primary tumors and metastatic foci, and the lack of tumor-infiltrating lymphocytes (TILs). Here, the authors constructed a novel cellular membrane nanovesicles platform (M/IR NPs) based on homologous targeting and near-infrared (NIR) responsive release strategy to potentiate PD-1/PD-L1 blockade therapy against metastatic tumors. In tumor-bearing mice, biomimetic M/IR NPs targeted both primary tumors and their lung metastases. Upon laser irradiation, M/IR NPs reduced cancer-associated fibroblasts (CAFs) in tumor microenvironment, thus increasing the penetration of TILs. When shed from homologous tumor cell membranes, positively charged nanoparticles (IR NPs) core can capture released tumor-associated antigens, thereby enhancing the antigen-presenting ability of DCs to activate cytotoxic T lymphocytes. When the photothermal conversion temperature under NIR-laser is higher than 42 °C, M/IR NPs initiated the rupture of cell membranes and the responsive release of PD-1/PD-L1 inhibitor BMS, which significantly attenuated tumor-associated immunosuppression and synergistically induced T cellular immunity to inhibit the tumor growth and metastasis. Overall, biomimetic M/IR NPs can improve the targeting and therapeutic efficacy of anti-PD therapy in primary tumors and metastases, opening up a new avenue for the diagnosis and treatment of metastatic tumors in the future.
40
Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery
Ronnie H. Fang, Che‐Ming Jack Hu, Brian T. Luk et al. · Nano Letters · 2014 · 1.5K citations · Full text
Pharmacy, Immunology, Pharmaceutics +17
Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
Esra A. Akbay, Shohei Koyama, Julián Carretero et al. · Cancer Discovery · 2013 · 1.2K citations · Full text
Medicine, Immunology, Oncology +17